Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. TMO
TMO logo

TMO Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
530.080
Open
523.110
VWAP
524.89
Vol
1.99M
Mkt Cap
195.70B
Low
518.000
Amount
1.04B
EV/EBITDA(TTM)
20.33
Total Shares
371.62M
EV
221.17B
EV/OCF(TTM)
28.29
P/S(TTM)
4.38
Thermo Fisher Scientific Inc. is engaged in accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, the discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, it provides instruments and the supporting consumables, software and services that are used for a range of applications. Its Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Biopharma Services segment offer virtually everything needed for the laboratory. It also provides purification and filtration technologies.
Show More

Events Timeline

(ET)
2026-04-09
08:10:00
Thermo Fisher Collaborates with Precision Health Research to Advance Biobank Initiative
select
2026-03-24 (ET)
2026-03-24
08:10:00
Thermo Fisher Completes $8.875B Acquisition of Clario
select

News

CNBC
4.5
04-17CNBC
Wall Street Optimism Rises Amid Ceasefire Hopes
  • Market Rebound: The S&P 500 and Nasdaq Composite reached all-time highs this week, with the S&P 500 surpassing 7,100 for the first time, reflecting strong investor confidence in economic recovery and suggesting further upward momentum for equities.
  • Earnings Expectations: According to FactSet, the S&P 500 is projected to have a blended growth rate of 12.5% in Q1, with 78% of reporting companies exceeding expectations, providing a positive backdrop for the upcoming earnings season that could further bolster market confidence.
  • Oil Price Volatility: While oil prices have fallen to around $80 per barrel, significantly below the $110 peak during the conflict, the market must remain vigilant regarding the potential impacts of U.S.-Iran tensions on global supply chains, particularly concerning the safety of transit through the Strait of Hormuz.
  • Technical Fragility: Despite the market's strong short-term performance, analyst Craig Johnson warns that the rapid transition from oversold to overbought conditions masks underlying macroeconomic risks, urging investors to remain cautious and focus on high-quality investment opportunities.
seekingalpha
3.5
04-17seekingalpha
OpenAI Launches AI Model to Accelerate Drug Discovery
  • Model Launch: OpenAI has introduced the GPT-Rosalind model aimed at accelerating the drug discovery process, particularly in the early stages from target discovery to drug approval, which is expected to significantly shorten the current 10-15 year timeline and enhance biological research efficiency.
  • Diverse Functionality: The model supports tasks such as evidence synthesis, hypothesis generation, and experimental planning, enabling scientists to conduct biology-related research more efficiently, marking a significant technological advancement in the life sciences sector.
  • Partnerships: OpenAI is collaborating with clients including Amgen (AMGN), Moderna (MRNA), and Thermo Fisher Scientific (TMO) to implement GPT-Rosalind across their workflows, further driving innovation and efficiency in the industry.
  • Research Tool Integration: The accompanying Codex life sciences research plugin will connect to over 50 scientific tools and data sources, enhancing scientists' flexibility in using research tools and promoting interdisciplinary collaboration.
Barron's
8.0
04-09Barron's
Dividend Stocks Triumphed in the Battle. Here's Why They May Prevail in the Aftermath.
  • Dividend-Paying Stocks as a Safe Haven: Dividend-paying stocks have provided investors with a refuge amid the ongoing conflict in the Middle East.

  • Continued Performance Outlook: These stocks are expected to maintain their performance even if a cease-fire is established.

Globenewswire
2.0
04-09Globenewswire
Pharmaceutical Industry Accelerates AI Compliance Transformation
  • AI-Driven Compliance Monitoring: Pharmaceutical manufacturers are shifting towards AI-driven real-time monitoring systems that dynamically assess compliance throughout the production process, thereby reducing human error and enhancing data integrity to meet increasingly stringent regulatory demands.
  • FDA Support for New Technologies: The U.S. FDA encourages the adoption of advanced manufacturing technologies and continuous production models, which is driving the pharmaceutical industry towards intelligent, automated compliance infrastructures, reducing the risk of manufacturing failures and supply disruptions.
  • Rise of Pharma 4.0: The emergence of the Pharma 4.0 concept signifies a significant evolution in pharmaceutical development and manufacturing, integrating AI, robotics, and advanced analytics to enhance productivity and product quality while promoting data-driven decision-making.
  • Significant Market Potential: The global pharmaceutical manufacturing market is expected to reach $1 trillion, with investments increasingly directed towards automation and digital infrastructure, indicating a strategic shift in companies' focus towards compliance and efficiency.
Newsfilter
7.5
04-09Newsfilter
Pharmaceutical Industry Shifts to AI-Driven Compliance
  • AI-Driven Compliance Transformation: Pharmaceutical manufacturers are increasingly integrating artificial intelligence into production workflows for real-time compliance monitoring, replacing traditional manual checks and retrospective audits, thereby enhancing production efficiency and reducing human error risks.
  • FDA Support for New Technologies: The U.S. Food and Drug Administration (FDA) is promoting the adoption of advanced manufacturing technologies, encouraging companies to implement real-time data monitoring to ensure product quality and minimize manufacturing failure risks, which introduces new compliance standards for the industry.
  • Rise of Pharma 4.0: The emergence of the Pharma 4.0 concept signifies a significant transformation in the pharmaceutical industry, integrating artificial intelligence, robotics, and data analytics to enhance production efficiency and product quality while driving data-driven decision-making processes.
  • Significant Market Potential: The global pharmaceutical manufacturing market is projected to reach $1 trillion, with increasing investments in automation and digital infrastructure, indicating the industry's focus on intelligent manufacturing and compliance will drive sustainable growth.
Barron's
8.0
04-08Barron's
Micron Shares and 14 Additional 'Dividend Growth' Stocks with Significant Potential
  • Current Market Challenge: Finding stocks with attractive yields is increasingly difficult in the current market environment.
  • Investment Strategy: Investors are advised to focus on companies that have a history of raising their dividends and may do so again in the near future.
Wall Street analysts forecast TMO stock price to rise
19 Analyst Rating
Wall Street analysts forecast TMO stock price to rise
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
580.00
Averages
658.89
High
750.00
Current: 0.000
sliders
Low
580.00
Averages
658.89
High
750.00
Barclays
Overweight
maintain
$650 -> $625
AI Analysis
2026-04-14
New
Reason
Barclays
Price Target
$650 -> $625
AI Analysis
2026-04-14
New
maintain
Overweight
Reason
Barclays lowered the firm's price target on Thermo Fisher to $625 from $650 and keeps an Overweight rating on the shares. The firm adjusted targets in the life science and diagnostic tools group as part of a Q1 preview. Barclays likes the setup for the sector but says it is "not without risk." Sentiment is at all-time lows and Barclays still believes in the "last-cut thesis (for the most part)," the analyst tells investors in a research note.
Citi
Patrick Donnelly
Buy
maintain
$685
2026-04-07
Reason
Citi
Patrick Donnelly
Price Target
$685
2026-04-07
maintain
Buy
Reason
Citi analyst Patrick Donnelly added an "upside 90-day catalyst watch" on shares of Thermo Fisher while keeping a Buy rating on the name with a $685 price target ahead of the Q1 report. Citi believes the stock's recent selloff does not reflect its guidance and the recent Clario acquisition.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for TMO
Unlock Now

Valuation Metrics

The current forward P/E ratio for Thermo Fisher Scientific Inc (TMO.N) is 21.46, compared to its 5-year average forward P/E of 24.28. For a more detailed relative valuation and DCF analysis to assess Thermo Fisher Scientific Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
24.28
Current PE
21.46
Overvalued PE
27.06
Undervalued PE
21.50

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
20.85
Current EV/EBITDA
16.48
Overvalued EV/EBITDA
22.75
Undervalued EV/EBITDA
18.96

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
4.88
Current PS
3.78
Overvalued PS
5.53
Undervalued PS
4.22

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

what stock to buy
Intellectia · 93 candidates
Market Cap: >= 10.00BQuarter Eps Yoy Growth: >= 5.0%Pe Ttm: 10 - 35Moving Average Relationship: PriceAboveMA200Is Index Component: GSPC
Ticker
Name
Market Cap$
top bottom
GOOG logo
GOOG
Alphabet Inc
3.86T
AAPL logo
AAPL
Apple Inc
3.81T
AMZN logo
AMZN
Amazon.com Inc
2.58T
JNJ logo
JNJ
Johnson & Johnson
573.15B
MU logo
MU
Micron Technology Inc
481.05B
BAC logo
BAC
Bank of America Corp
381.22B
top stocks in health sector
Intellectia · 38 candidates
Market Cap: >= 10.00BSector: Healthcare, Healthcare Services & EquipmentIndustry: Biotechnology & Medical Research, Healthcare Equipment & Supplies, Healthcare Providers & Services, PharmaceuticalsAnalyst Consensus: Strong Buy, Moderate BuyRevenue 5yr Cagr: >= 5List Exchange: XNYS, XNAS, XASEReturn On Equity: >= 10.0%
Ticker
Name
Market Cap$
top bottom
LLY logo
LLY
Eli Lilly and Co
866.87B
ABBV logo
ABBV
AbbVie Inc
364.65B
AZN logo
AZN
AstraZeneca PLC
293.00B
MRK logo
MRK
Merck & Co Inc
282.35B
UNH logo
UNH
UnitedHealth Group Inc
254.55B
AMGN logo
AMGN
Amgen Inc
188.63B
list drone companies
Intellectia · 23 candidates
Market Cap: >= 20.00MThemes: Aerospace & Defense, RoboticsMonthly Average Dollar Volume: >= 20,000
Ticker
Name
Market Cap$
top bottom
RTX logo
RTX
RTX Corp
278.97B
TMO logo
TMO
Thermo Fisher Scientific Inc
184.15B
ISRG logo
ISRG
Intuitive Surgical Inc
175.03B
BA logo
BA
Boeing Co
168.25B
DE logo
DE
Deere & Co
160.45B
LMT logo
LMT
Lockheed Martin Corp
149.43B
Humanoid robotics industry
Intellectia · 11 candidates
Themes: Robotics
Ticker
Name
Market Cap$
top bottom
TMO logo
TMO
Thermo Fisher Scientific Inc
186.47B
BA logo
BA
Boeing Co
181.50B
ISRG logo
ISRG
Intuitive Surgical Inc
174.07B
DE logo
DE
Deere & Co
159.30B
LMT logo
LMT
Lockheed Martin Corp
154.56B
NOC logo
NOC
Northrop Grumman Corp
107.31B
which stocks have only buy ratings?
Intellectia · 34 candidates
Market Cap: >= 20.00BAnalyst Consensus: Strong BuyList Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePriceIs Index Component: GSPC, NDX
Ticker
Name
Market Cap$
top bottom
NVDA logo
NVDA
NVIDIA Corp
4.46T
MSFT logo
MSFT
Microsoft Corp
3.05T
AVGO logo
AVGO
Broadcom Inc
1.58T
AMD logo
AMD
Advanced Micro Devices Inc
325.19B
UNH logo
UNH
UnitedHealth Group Inc
262.11B
ABT logo
ABT
Abbott Laboratories
192.95B
suggest a few for swing trade
Intellectia · 7 candidates
Market Cap: >= 1000.00MRegion: USThemes: RoboticsRsi Category: moderateList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceAboveMA200One Week Rise Prob: >= 0Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
ROK logo
ROK
Rockwell Automation Inc
45.54B
ISRG logo
ISRG
Intuitive Surgical Inc
175.44B
TMO logo
TMO
Thermo Fisher Scientific Inc
193.72B
BA logo
BA
Boeing Co
183.29B
LMT logo
LMT
Lockheed Martin Corp
152.87B
NOC logo
NOC
Northrop Grumman Corp
103.28B
rsi below 35 in the s&p500
Intellectia · 22 candidates
Rsi Category: oversoldIs Index Component: GSPC
Ticker
Name
Market Cap$
top bottom
TMO logo
TMO
Thermo Fisher Scientific Inc
192.95B
CRM logo
CRM
Salesforce Inc
175.96B
ACN logo
ACN
Accenture PLC
147.75B
BKNG logo
BKNG
Booking Holdings Inc
137.64B
PANW logo
PANW
Palo Alto Networks Inc
124.32B
INTU logo
INTU
Intuit Inc
108.41B
most bullish ticker 2026
Intellectia · 21 candidates
Market Cap: >= 5.00BMarket Cap Category: large, midAnalyst Consensus: Strong BuyTarget Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA200One Month Rise Prob: >= 60
Ticker
Name
Market Cap$
top bottom
GLBE logo
GLBE
Global-E Online Ltd
5.91B
ALK logo
ALK
Alaska Air Group Inc
6.40B
CRDO logo
CRDO
Credo Technology Group Holding Ltd
23.10B
TMO logo
TMO
Thermo Fisher Scientific Inc
192.95B
IMVT logo
IMVT
Immunovant Inc
5.42B
COGT logo
COGT
Cogent Biosciences Inc
6.22B
best swing stock for today ?
Intellectia · 148 candidates
Market Cap: >= 1000.00MRsi Category: moderateRelative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20Week Price Change Pct: $2.00 - $10.00
Ticker
Name
Market Cap$
top bottom
TMO logo
TMO
Thermo Fisher Scientific Inc
239.06B
KLAC logo
KLAC
KLA Corp
199.72B
AMGN logo
AMGN
Amgen Inc
185.02B
GEV logo
GEV
GE Vernova Inc
181.21B
IBKR logo
IBKR
Interactive Brokers Group Inc
128.56B
ARM logo
ARM
Arm Holdings PLC
120.87B
stocks that will pop today
Intellectia · 540 candidates
Relative Vol: >= 1.50Weekly Average Turnover: >= 1,000,000Week Price Change Pct: >= $0.00
Ticker
Name
Market Cap$
top bottom
MU logo
MU
Micron Technology Inc
437.95B
COST logo
COST
Costco Wholesale Corp
436.26B
AMD logo
AMD
Advanced Micro Devices Inc
406.68B
MS logo
MS
Morgan Stanley
290.20B
INTC logo
INTC
Intel Corp
258.77B
TMO logo
TMO
Thermo Fisher Scientific Inc
239.06B

Whales Holding TMO

O
ODDO BHF Asset Management SAS
Holding
TMO
+76.31%
3M Return
E
Evelyn Partners Investment Management LLP
Holding
TMO
+66.48%
3M Return
S
Schroder Investment Management Limited
Holding
TMO
+60.90%
3M Return
A
Architas Multi-Manager Europe Ltd.
Holding
TMO
+54.00%
3M Return
O
Ofi Invest Asset Management
Holding
TMO
+46.79%
3M Return
N
Needham Investment Management, LLC
Holding
TMO
+34.92%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Thermo Fisher Scientific Inc (TMO) stock price today?

The current price of TMO is 526.6 USD — it has increased 2.05

What is Thermo Fisher Scientific Inc (TMO)'s business?

Thermo Fisher Scientific Inc. is engaged in accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, the discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, it provides instruments and the supporting consumables, software and services that are used for a range of applications. Its Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Biopharma Services segment offer virtually everything needed for the laboratory. It also provides purification and filtration technologies.

What is the price predicton of TMO Stock?

Wall Street analysts forecast TMO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TMO is658.89 USD with a low forecast of 580.00 USD and a high forecast of 750.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Thermo Fisher Scientific Inc (TMO)'s revenue for the last quarter?

Thermo Fisher Scientific Inc revenue for the last quarter amounts to 12.21B USD, increased 7.20

What is Thermo Fisher Scientific Inc (TMO)'s earnings per share (EPS) for the last quarter?

Thermo Fisher Scientific Inc. EPS for the last quarter amounts to 5.20 USD, increased 8.79

How many employees does Thermo Fisher Scientific Inc (TMO). have?

Thermo Fisher Scientific Inc (TMO) has 125000 emplpoyees as of April 19 2026.

What is Thermo Fisher Scientific Inc (TMO) market cap?

Today TMO has the market capitalization of 195.70B USD.